Drugs / FT819
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06308978 | Mar 2024 → Sep 2027 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy, lupus nephritis, systemic lupus erythematosus +1 | Fate Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT04629729 | Jul 2021 → Jun 2025 overdue | B-cell chronic lymphocytic leukemia, precursor B-cell acute lymphoblastic leukemia | Fate Therapeutics | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07570862 | Jul 2026 → Jul 2029 expected | lupus nephritis, systemic lupus erythematosus | Fate Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT819 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04629729 ↗ |
| Modality | Cell therapy | “allogeneic T cells derived from a clonal, TCR knockout iPSC line” NCT07570862 ↗ |
| Route | Intravenous | “FT819 will be administered as intravenous (IV) infusion at planned dose levels.” NCT06308978 ↗ |
| Target | CD19 | “express CD19-targeted CAR regulated by the TRAC locus” NCT07570862 ↗ |